Hospital de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2017

  1. Phenotype of mutations in the promoter region of the β-globin gene

    Journal of Clinical Pathology, Vol. 70, Núm. 10, pp. 874-878

2011

  1. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

    Current Medical Research and Opinion, Vol. 27, Núm. 5, pp. 951-960

2010

  1. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

    Leukemia Research, Vol. 34, Núm. 9, pp. 1143-1150

  2. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements

    Annals of Hematology, Vol. 89, Núm. 2, pp. 147-154

2007

  1. Hemoglobina Fannin-Lubbock II [β111(G13)Val → Leu y β119(GH2)Gly → Asp]: Descripción de 4 nuevos casos

    Medicina Clinica, Vol. 129, Núm. 10, pp. 379-381

2000

  1. Hb Johnstown [β109 (G11) Val→Leu]: Second case described and associated for the first time with β0-thalassemia in two Spanish families

    American Journal of Hematology, Vol. 65, Núm. 4, pp. 298-301